<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04589429</url>
  </required_header>
  <id_info>
    <org_study_id>678-9/2020</org_study_id>
    <nct_id>NCT04589429</nct_id>
  </id_info>
  <brief_title>Adding Nalbuphine for Control of Intrathecal Morphine Pruritus</brief_title>
  <official_title>Does Adding Nalbuphine to Intrathecal Morphine Reduce Morphine Induced Pruritus? A Randomized, Double Blind, Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intrathecal morphine causes intense itching which is very bothersome. Nalbuphine antagonizes&#xD;
      this effect when given intravenously. This trial is to find out if nalbuphine added to&#xD;
      intrathecal morphine has an effect on morphine related pruritus while still maintaining&#xD;
      adequate analgesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be performed in MiniaUniversity Hospitals, after obtaining approval from the&#xD;
      local ethics committee. All patients will have a peripheral IV cannula 18 G inserted;&#xD;
      standard non-invasive monitors will be applied. Patients undergoing major abdominal surgery&#xD;
      will be divided into 2 groups to receive intrathecal morphine 300 micrograms with or without&#xD;
      nalbuphine 1mg prior to anesthesia. General anesthesia is then given to patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pruritus</measure>
    <time_frame>2 hours postoperatively</time_frame>
    <description>Pruritus score (1: no pruritus; 2: mild pruritus, treatment not requested; 3: moderate pruritus, treatment requested; 4: severe pruritus).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pruritus</measure>
    <time_frame>4 hours postoperatively</time_frame>
    <description>Pruritus score (1: no pruritus; 2: mild pruritus, treatment not requested; 3: moderate pruritus, treatment requested; 4: severe pruritus).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pruritus</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Pruritus score (1: no pruritus; 2: mild pruritus, treatment not requested; 3: moderate pruritus, treatment requested; 4: severe pruritus).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative pain</measure>
    <time_frame>2 hours postoperative</time_frame>
    <description>assessed with a verbal numeric pain score(NRS) where 0: no pain; 10: worst imaginable pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative pain</measure>
    <time_frame>4 hours postoperative</time_frame>
    <description>assessed with a verbal numeric pain score(NRS) where 0: no pain; 10: worst imaginable pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative pain</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>assessed with a verbal numeric pain score(NRS) where 0: no pain; 10: worst imaginable pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative nausea and vomiting</measure>
    <time_frame>2 hours postoperative</time_frame>
    <description>four-point rating score (1: no nausea or vomiting, 2: queasy, 3: severe nausea, 4: vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative nausea and vomiting</measure>
    <time_frame>4 hours postoperative</time_frame>
    <description>four-point rating score (1: no nausea or vomiting, 2: queasy, 3: severe nausea, 4: vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative nausea and vomiting</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>four-point rating score (1: no nausea or vomiting, 2: queasy, 3: severe nausea, 4: vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation</measure>
    <time_frame>2 hours postoperative</time_frame>
    <description>four-point sedation score (1: fully awake; 2: somnolent, responds to call; 3: somnolent, responds to tactile stimulation; 4: asleep, responds to painful stimulation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation</measure>
    <time_frame>4 hours postoperative</time_frame>
    <description>four-point sedation score (1: fully awake; 2: somnolent, responds to call; 3: somnolent, responds to tactile stimulation; 4: asleep, responds to painful stimulation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>four-point sedation score (1: fully awake; 2: somnolent, responds to call; 3: somnolent, responds to tactile stimulation; 4: asleep, responds to painful stimulation).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Pruritus</condition>
  <condition>Pain, Postoperative</condition>
  <condition>Nausea, Postoperative</condition>
  <condition>Vomiting, Postoperative</condition>
  <arm_group>
    <arm_group_label>MN group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intrathecal morphine 300 micrograms+2mg nalbuphine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intrathecal morphine 300 micrograms</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine 10 MG/ML</intervention_name>
    <description>intrathecal morphine 300 micrograms</description>
    <arm_group_label>M group</arm_group_label>
    <arm_group_label>MN group</arm_group_label>
    <other_name>morphine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nalbuphine Hydrochloride 10 MG/ML</intervention_name>
    <description>intrathecal nalbuphine 2mg.</description>
    <arm_group_label>MN group</arm_group_label>
    <other_name>nalbuphine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients.&#xD;
&#xD;
          -  Age 18-80yrs.&#xD;
&#xD;
          -  Elective major abdominal surgery under general anesthesia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to participate.&#xD;
&#xD;
          -  Skin or systemic disease with itching. Any condition which precludes performing spinal&#xD;
             injection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sohair A Megalla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anesthesia and ICU department, Faculty of Medicine, Minia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sohair A Megalla, MD</last_name>
    <phone>+20 120 003 6447</phone>
    <email>Sohair.Adeeb@minia.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>anesthesia&amp;ICU department</name>
      <address>
        <city>Minya</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>sohair A Megalla, MD</last_name>
      <phone>01200036447</phone>
      <email>Sohair.Adeeb@minia.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 27, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Minia University</investigator_affiliation>
    <investigator_full_name>Sohair Adeeb</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <keyword>pruritus</keyword>
  <keyword>intrathecal morphine</keyword>
  <keyword>intrathecal nalbuphine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Nalbuphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

